Alimera, Bayer lead drug stocks higher
August 31, 2010 at 10:45 AM EDT
Alimera Sciences lead drug stocks higher in early activity as shares of the biotech group jump on news that its ophthalmology drug candidate Iluvien has received priority review status from the U.S. Food and Drug Administration.
